Patents by Inventor Dhiman Sarkar
Dhiman Sarkar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10017583Abstract: Disclosed herein is an improved process for the preparation of nanostructured oxidized/carboxy cellulose with high carboxy content and high yield, by subjecting non-wood, lignocellulose, sugarcane bagasse derived a-cellulose or cotton cellulose to oxidation at suitable temperature, wherein the particle shape is spherical, particle size of synthesized carboxy cellulose is in the range of 1-100 nm and degree of polymerization (DP) is in the range 50-70 Further the present invention provides pharmaceutical composition comprising of nanostructured oxidized/carboxy celluloses preferably 6-carboxy cellulose, and 2,3,6-tricarboxycellulose alone or in association with one or more pharmaceutically acceptable carrier(s) or excipient(s) for treatment of microbial infections. The carboxycelluloses were efficient in stabilizing multi-walled carbon nanotubes and single-walled carbon nanotubes in aqueous media.Type: GrantFiled: June 3, 2014Date of Patent: July 10, 2018Assignee: Council of Scientific & Industrial ResearchInventors: Anjanikumar Jyotiprasad Varma, Priyanka Radheyshyam Sharma, Dhiman Sarkar
-
Patent number: 9801918Abstract: The present invention describes the use of pharmaceutical compositions including compounds of formula 2 (below) for treatment of infections related to M. tuberculosis and for anti-proliferative activity.Type: GrantFiled: May 31, 2016Date of Patent: October 31, 2017Assignee: Council of Scientific & Industrial ResearchInventors: Swati Pramod Joshi, Roshan Rajan Kulkarni, Ketaki Dilip Shurpali, Sampa Sarkar, Dhiman Sarkar
-
Patent number: 9670523Abstract: The present invention discloses functional nitrite reductase as a potential drug target for anti-tubercular drug development. The present invention also relates to the development of an easy method for identification of nitrite in clinical samples as well as its correlation with the severity of the disease. Presence of active as well as dormant/latent stages of Mycobacterium tuberculosis (MTB) could be identified from nitrite in clinical samples like sputum of potential TB patients.Type: GrantFiled: November 3, 2014Date of Patent: June 6, 2017Assignee: Council of Scientific and Industrial ResearchInventor: Dhiman Sarkar
-
Patent number: 9663548Abstract: Disclosed herein is 10-?/?-D-Arabinofuranosylundecenes of general Formula (II) or pharmaceutically acceptable salts thereof as anti-mycobacterial agents in vitro; (II) wherein R, R1 and R? are as defined herein in the specification. The present invention also discloses a simple stereoselective synthesis 10-?/?-D-Arabinofuranosylundecenes of Formula (II) to target enzymes involved in the biosynthesis of cell wall of Mycobacterium and thus useful as inhibitors in the Mycobacterium tuberculosis drug development.Type: GrantFiled: September 14, 2012Date of Patent: May 30, 2017Assignee: Council of Scientific and Industrial ResearchInventors: Ramana Venkata Chepuri, Dhiman Sarkar, Rahul Shivaji Patil, Sampa Sarkar
-
Patent number: 9527827Abstract: This invention relates to diterpenes of general formula (1) belonging to labdane class, isolated from Leucas stelligera, being useful for prevention, treatment, inhibition or controlling growth and proliferation of mycobacterial activity in mammals. The invention further discloses process for isolation of the fractions containing the same.Type: GrantFiled: August 6, 2012Date of Patent: December 27, 2016Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Swati Joshi, Roshan Rajan Kulkarni, Ketaki Dilip Shurpali, Sampa Sarkar, Dhiman Sarkar
-
Publication number: 20160271196Abstract: The present invention describes use of compounds of formula 1 or 2 or their compositions for the treatment of leukemia and use of compound of formula 1 or its composition for treatment of infections caused due to M. tuberculosis. The invention further discloses use of compound of formula 3 for the conversion of solar energy into electric current in dye sensitized solar cells.Type: ApplicationFiled: May 31, 2016Publication date: September 22, 2016Inventors: Swati Pramod JOSHI, Roshan Rajan KULKARNI, Ketaki Dilip SHURPALI, Sampa SARKAR, Dhiman SARKAR
-
Patent number: 9376402Abstract: Triazole derivatives useful as anti-tubercular compounds; process for preparation of the triazoles and a method for inhibiting growth of Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Ra using the triazoles.Type: GrantFiled: September 23, 2014Date of Patent: June 28, 2016Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Dhiman Sarkar, Sunita Ranjan Deshpande, Shailaja Pramod Maybhate, Anjali Prabhakar Likhite, Sampa Sarkar, Arshad Khan, Preeti Madhukar Chaudhary, Sayalee Ramchandra Chavan
-
Publication number: 20160130368Abstract: Disclosed herein is an improved process for the preparation of nanostructured oxidized/carboxy cellulose with high carboxy content and high yield, by subjecting non-wood, lignocellulose, sugarcane bagasse derived a-cellulose or cotton cellulose to oxidation at suitable temperature, wherein the particle shape is spherical, particle size of synthesized carboxy cellulose is in the range of 1-100 nm and degree of polymerization (DP) is in the range 50-70 Further the present invention provides pharmaceutical composition comprising of nanostructured oxidized/carboxy celluloses preferably 6-carboxy cellulose, and 2,3,6-tricarboxycellulose alone or in association with one or more pharmaceutically acceptable carrier(s) or excipient(s) for treatment of microbial infections. The carboxycelluloses were efficient in stabilizing multi-walled carbon nanotubes and single-walled carbon nanotubes in aqueous media.Type: ApplicationFiled: June 3, 2014Publication date: May 12, 2016Inventors: Anjanikumar Jyoti-Prasad Varma, Priyanka Radheyshyam Sharma, Dhiman Sarkar
-
Publication number: 20150259372Abstract: Disclosed herein is 10-?/?-D-Arabinofuranosylundecenes of general Formula (II) or pharmaceutically acceptable N salts thereof as anti-mycobacterial agents in vitro; (II) wherein R, R1 and R? are as defined herein in the specification. The present invention also discloses a simple stereoselective synthesis 10-?/?-D-Arabinofuranosylundecenes of Formula (II) to target enzymes involved in the biosynthesis of cell wall of Mycobacterium and thus useful as inhibitors in the Mycobacterium tuberculosis drug development.Type: ApplicationFiled: September 14, 2012Publication date: September 17, 2015Applicant: Council of Scientific & Industrial ResearchInventors: Ramana Venkata Chepuri, Dhiman Sarkar, Rahul Shivaji Patil, Sampa Sarkar
-
Patent number: 9028893Abstract: Active fractions exhibiting anti-tuberculous activity from the plant Byttneria herbecea (family—Sterculiaceae) are described. Methanol extracts of the aerial part of Byttneria herbecea exhibited activity against MtbGS in primary screening of biosynthetic assay. Subsequent fractionation was carried out in organic solvents. Out of all these, two fractions (fraction D and K) are exhibiting inhibitory activity against M. tuberculosis glutamine synthetase activity. These fractions D and K are inhibiting 74% and 44% respectively at 7.5 mg/ml concentrations. The determined IC50 value of the fraction K is found to be 4.5 mg/ml from the dose response curve against the purified Mycobacterium tuberculosis Glutamine Synthetase. The IC50 value for M. bovis BCG is 1.56 ?g/ml. It was observed that there was no significant effect on proliferation of HL-60 cell line at 10×MIC levels of the hits. This data indicated that these compounds could be initially considered to be safe.Type: GrantFiled: September 21, 2012Date of Patent: May 12, 2015Assignee: Council of Scientific & Industrial ResearchInventors: Dhiman Sarkar, Swati Pramod Joshi, Upasana Singh, Ketaki Dilip Shurpali, Roshan Rajan Kulkarni
-
Publication number: 20150118702Abstract: The present invention discloses functional nitrite reductase as a potential drug target for anti-tubercular drug development. The present invention also relates to the development of an easy method for identification of nitrite in clinical samples as well as its correlation with the severity of the disease. Presence of active as well as dormant/latent stages of Mycobacterium tuberculosis (MTB) could be identified from nitrite in clinical samples like sputum of potential TB patients.Type: ApplicationFiled: November 3, 2014Publication date: April 30, 2015Inventor: Dhiman Sarkar
-
Publication number: 20150073026Abstract: Triazole derivatives useful as anti-tubercular compounds; process for preparation of the triazoles and a method for inhibiting growth of Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Ra using the triazoles.Type: ApplicationFiled: September 23, 2014Publication date: March 12, 2015Inventors: Dhiman SARKAR, Sunita Ranjan DESHPANDE, Shailaja Pramod MAYBHATE, Anjali Prabhakar LIKHITE, Sampa SARKAR, Arshad KHAN, Preeti Madhukar CHAUDHARY, Sayalee Ramchandra CHAVAN
-
Publication number: 20150051277Abstract: The present invention describes use of compounds of formula 1 or 2 or their compositions for the treatment of leukemia and use of compound of formula 1 or its composition for treatment of infections caused due to M. tuberculosis. The invention further discloses use of compound of formula 3 for the conversion of solar energy into electric current in dye sensitized solar cells.Type: ApplicationFiled: August 6, 2012Publication date: February 19, 2015Inventors: Swati Pramod Joshi, Roshan Rajan Kulkarni, Ketaki Dilip Shurpali, Sampa Sarkar, Dhiman Sarkar
-
Patent number: 8877452Abstract: The present invention discloses functional nitrite reductase as a potential drug target for anti-tubercular drug development. The present invention also relates to the development of an easy method for identification of nitrite in clinical samples as well as its correlation with the severity of the disease. Presence of active as well as dormant/latent stages of Mycobacterium tuberculosis (MTB) could be identified from nitrite in clinical samples like sputum of potential TB patients.Type: GrantFiled: February 27, 2013Date of Patent: November 4, 2014Assignee: Council of Scientific and Industrial ResearchInventor: Dhiman Sarkar
-
Patent number: 8865910Abstract: Invention provides antitubercular compounds selected from propargylated 1,2,3 triazoles of Formula I, wherein, X is sulfur(S) or a sulphone (A), n, m represent independently an integer O or 1, with the provision that when ‘n’ is 1, ‘m’ is 1; R1 is hydrogen; C1-C6 linear or branched alkyl group optionally substituted with aryl group; halogen; or aryl group optionally substituted with —OCH3, halogen, and nitro; R2 and R3 are selected from the group consisting of hydrogen, C1-C6 alkyl optionally substituted with heterocyclic ring of 5 to 6 ring atoms containing one to three hetero atoms selected from oxygen, sulfur, nitrogen, which may be substituted with alkyl, arylalkyl, linear or branched alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or allyl or propargyl groups consisting of 1 to 6 carbon atoms; Z is C1-C6 alkyl optionally substituted with heterocyclic ring of 1 to 6 ring atoms, containing one to three hetero atoms selected from oxygen, sulfur, nitrogen, which may be substituted with arylalkyl,Type: GrantFiled: March 14, 2011Date of Patent: October 21, 2014Assignee: Council of Scientific & Industrial ResearchInventors: Dhiman Sarkar, Sunita Ranjan Deshpande, Shailaja Pramod Maybhate, Anjali Prabhakar Likhite, Sampa Sarkar, Arshad Khan, Preeti Madhukar Chaudhary, Sayalee Ramchandra Chavan
-
Publication number: 20140242626Abstract: The present invention discloses functional nitrite reductase as a potential drug target for anti-tubercular drug development. The present invention also relates to the development of an easy method for identification of nitrite in clinical samples as well as its correlation with the severity of the disease. Presence of active as well as dormant/latent stages of Mycobacterium tuberculosis (MTB) could be identified from nitrite in clinical samples like sputum of potential TB patients.Type: ApplicationFiled: February 27, 2013Publication date: August 28, 2014Inventor: Dhiman Sarkar
-
Publication number: 20140171498Abstract: This invention relates to diterpenes of general formula (1) belonging to labdane class, isolated from Leucas stelligera, being useful for prevention, treatment, inhibition or controlling growth and proliferation of mycobacterial activity in mammals. The invention further discloses process for isolation of the fractions containing the same.Type: ApplicationFiled: August 6, 2012Publication date: June 19, 2014Applicant: Council of Scientific & Indusrtial ReasearchInventors: Swati Joshi, Roshan Rajan Kulkarni, Ketaki Dilip Shurpali, Sampa Sarkar, Dhiman Sarkar
-
Publication number: 20130060045Abstract: Invention provides antitubercular compounds selected from propargylated 1,2,3 triazoles of Formula I, wherein, X is sulfur (S) or a sulphone (A), n, m represent independently an integer O or 1, with the provision that when ‘n’ is 1, ‘m’ is 1; R1 is hydrogen; C1-C6 linear or branched alkyl group optionally substituted with aryl group; halogen; or aryl group optionally substituted with —OCH3, halogen, and nitro; R2 and R3 are selected from the group consisting of hydrogen, C1-C6 alkyl optionally substituted with heterocyclic ring of 5 to 6 ring atoms containing one to three hetero atoms selected from oxygen, sulfur, nitrogen, which may be substituted with alkyl, arylalkyl, linear or branched alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or allyl or propargyl groups consisting of 1 to 6 carbon atoms; Z is C1-C6 alkyl optionally substituted with heterocyclic ring of 1 to 6 ring atoms, containing one to three hetero atoms selected from oxygen, sulfur, nitrogen, which may be substituted with arylalkylType: ApplicationFiled: March 14, 2011Publication date: March 7, 2013Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Dhiman Sarkar, Sunita Ranjan Deshpande, Shailaja Pramod Maybhate, Anjali, Prabhakar Likhite, Sampa Sarkar, Arshad Khan, Preeti Madhukar Chaudhary, Sayalee Ramchandra Chavan